Coherus Oncology, Inc.
CHRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12 | $10 | $8 | $54 |
| % Growth | 12.8% | 34.9% | -86% | – |
| Cost of Goods Sold | $4 | $3 | $3 | $34 |
| Gross Profit | $8 | $7 | $5 | $20 |
| % Margin | 67.8% | 66.9% | 65.1% | 37.5% |
| R&D Expenses | $27 | $26 | $24 | $21 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23 | $26 | $26 | $41 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Expenses | $52 | $52 | $50 | $63 |
| Operating Income | -$44 | -$45 | -$45 | -$42 |
| % Margin | -383.1% | -443.6% | -597.9% | -78% |
| Other Income/Exp. Net | -$0 | $1 | -$2 | -$8 |
| Pre-Tax Income | -$45 | -$45 | -$47 | -$51 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36 | $298 | -$57 | -$51 |
| % Margin | -307.1% | 2,903.9% | -744.4% | -93.6% |
| EPS | -0.31 | -0.36 | -0.49 | -0.44 |
| % Growth | 13.9% | 26.5% | -11.4% | – |
| EPS Diluted | -0.31 | -0.36 | -0.49 | -0.44 |
| Weighted Avg Shares Out | 116 | 116 | 116 | 115 |
| Weighted Avg Shares Out Dil | 116 | 116 | 116 | 115 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $5 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$41 | -$42 | -$44 | -$44 |
| % Margin | -356.3% | -405.4% | -581.7% | -81.9% |